Combination therapy for the treatment of solid and hematological cancers
- 专利权人:
- Arch Oncology; Inc.
- 发明人:
- Manning, Pamela T.,Puro, Robyn,Almagro, Juan C.,Karr, Robert W.,Capoccia, Benjamin J.
- 申请号：
- AU2018240377
- 公开号：
- AU2018240377A1
- 申请日:
- 2018.03.22
- 申请国别(地区):
- AU
- 年份:
- 2019
- 代理人:
- 摘要：
- Methods are provided for using anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, with other anti-cancer agents, more specifically, chemotherapeutic agents, which include but are not limited to anthracyclines, platinums, taxols, topisomerase inhibitors, anti-metabolites, anti-tumor antibiotics, mitotic inhibitors, and alkylating agents.
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- COMBINATION THERAPY FOR THE TREATMENT OF SOLID AND HEMATOLOGICAL CANCERS
- Combination of anti-HLA-DR or anti-TROP-2 antibody with microtubule inhibitor, PARP inhibitor, breton kinase inhibitor or phosphoinositide 3-kinase inhibitor significantly improves the therapeutic effect of cancer
- Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
- Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
- COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER
